Does slow weight loss in the first eight weeks mean an obesity medicine will not work? A new CagriSema analysis cannot settle that question for an individual. It does show why an early response threshold should not automatically become a stopping rule: participants below that threshold still had substantial average weight loss later in the trial.
On November 15, Novo Nordisk announced exploratory REDEFINE 1 findings presented at ObesityWeek 2026. The headline result—about 25% average weight loss—describes early responders using observed on-treatment data. It is not a new estimate for everyone starting CagriSema, and it does not establish a clinical decision rule.
What counted as an early response?
The sponsor divided CagriSema-treated adults into those who had lost at least 5% of their starting weight by week 8 and those who had lost less. It called these groups early and delayed responders. In this post hoc analysis, 67.8% were early responders; the reported group sizes were 1,367 and 649, respectively.
At week 68, observed average weight loss was 25.4% among early responders and 17.8% among delayed responders. Those figures come from the on-treatment period, according to the announcement’s table footnote. They describe two groups defined after treatment began, not two randomly assigned treatment strategies.
“Delayed responder” is therefore an analysis label, not a diagnosis. The lower early-loss group’s later average is the useful counterweight to the headline: crossing an eight-week threshold was not necessary for a substantial average reduction in this dataset. Neither group average predicts what will happen to a particular person.
The eight-week checkpoint came during dose escalation
The original randomized trial report enrolled 3,417 adults without diabetes who had obesity, or overweight with an obesity-related complication. Participants received CagriSema, either component alone, or placebo, alongside lifestyle intervention. The combination’s research target was a weekly injection containing 2.4 mg each of cagrilintide and semaglutide.
The protocol escalated doses over 16 weeks, with delays or reductions permitted. Week 8 was consequently an early checkpoint during escalation, rather than a test after a full maintenance period. These are study-design details, not instructions for taking or adjusting a medicine. The CagriSema profile explains the investigational combination.
The REDEFINE 1 registry record lists the main weight outcomes at week 68 and also records an eight-week weight-change outcome. Measuring weight at week 8, however, does not itself validate a rule for discontinuing treatment. That would require evidence about the consequences of applying the rule, including who would lose a later benefit.
Why 25.4% does not replace the original trial result
In the original paper, estimated average weight loss at week 68 was 20.4% with CagriSema and 3.0% with placebo under the treatment-policy estimand. That analysis addresses the randomized treatment assignment regardless of discontinuation or rescue intervention. Our guide to trial estimands explains why those choices matter.
The new 25.4% figure answers a narrower question: what was observed during treatment among people already classified as early responders? It changes both the population and the handling of follow-up. Placing it beside the original 20.4% as though the drug’s overall effect had increased would be misleading.
There are unresolved accounting questions, too. The announcement’s response groups total 2,016 people, whereas 2,108 were randomized to CagriSema. Its summary does not fully explain that difference or provide separate week-68 observation counts and confidence intervals for these averages. Without the original analysis materials, we cannot determine how missing observations affected each trajectory. The post hoc findings remain hypothesis-generating.
Physical function is a separate outcome
The announcement also reports a separate analysis of weight-related physical function. At week 68, 73.1% with CagriSema versus 49.1% with placebo met a meaningful within-person improvement threshold on the IWQOL-Lite-CT Physical Function questionnaire score. These percentages use an efficacy estimand assuming treatment adherence; they are not the observed early-responder weight-loss analysis.
A questionnaire can capture daily difficulties that a scale misses. It does not directly measure muscle strength, establish prevention of disability, or show that early weight loss caused the reported improvement. Keeping the outcomes separate makes both findings easier to understand.
What readers can use—and what remains unknown
Tolerability also shapes the meaning of continued-treatment results. The original trial reported gastrointestinal adverse events in 79.6% with CagriSema versus 39.9% with placebo, mostly transient and mild to moderate. Adverse events led to permanent treatment discontinuation in 5.9% versus 3.5%. These overall figures are not safety estimates for early or delayed responders.
The immediate value is a better question for reading trial news: who is included in the average, and what happened to people no longer observed on treatment? Our trial-reading guide offers a framework. A useful follow-up analysis would explain exclusions, missing data, uncertainty and whether the early threshold predicts outcomes in another population.
In its November 15 announcement, Novo Nordisk still described CagriSema as investigational and not approved in the United States. The conference analysis is not an approval or a reason to start, stop or change treatment. Its contribution is more modest: early weight-loss patterns differ, and a slow start should not be confused with a proven verdict about later response.



